Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab

World Journal of Gastroenterology

Volumn 19, Issue 4, 2013, Pages 590-593

  Duca, Ileana ^a   de la Piscina, Patricia Ramírez ^a   Estrada, Silvia ^a   Calderón, Rosario ^a   Spicakova, Katerina ^a   Urtasun, Leire ^a   Marra López, Carlos ^a   Zabaleta, Salvador ^a   Bengoa, Raquel ^a   Marcaide, María Asunción ^a   García Campos, Francisco ^a  

^a HOSPITAL TXAGORRITXU   (Spain)

Author keywords

Bile duct diseases; Infliximab; Monoclonal antibodies; Sclerosing cholangitis; Tumor necrosis factor alpha; Ulcerative colitis

Indexed keywords

ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BILIRUBIN; CORTICOSTEROID; HEMOGLOBIN; IMMUNOGLOBULIN G4; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; STEROL; UNCLASSIFIED DRUG; URODESOXYCHOLIC ACID;

ABDOMINAL PAIN; AGED; ANEMIA; ANKYLOSING SPONDYLITIS; ARTICLE; BLOODY DIARRHEA; CASE REPORT; DEFECATION URGENCY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; ENTERITIS; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; LIVER NECROSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCOLITIS; PRIMARY SCLEROSING CHOLANGITIS; PROCTALGIA; TENESMUS; ULCERATIVE COLITIS; WEIGHT REDUCTION;

EID: 84873651682     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i4.590     Document Type: Article

References (22)

1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-1122. [PMID: 11316157 DOI: 10.1111/j.1572-0241. 2001.03756.x]
2. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (NY) 2011; 7: 235-241. [PMID: 21857821]
3. Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol 2011; 17: 2702-2707. [PMID: 21734777 DOI: 10.3748/wjg.v17.i22.2702]
4. Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2008; 10: 597-605. [PMID: 19006617]
5. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1424-1429. [PMID: 17567879 DOI: 10.1002/ibd.20196]
6. Siemanowski B, Regueiro M. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Curr Treat Options Gastroenterol 2007; 10: 178-184. [PMID: 17547856]
7. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123: 903-912. [PMID: 16009830 DOI: 10.1001/archopht.123.7.903]
8. Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. A review of infliximab use in ulcerative colitis. Clin Ther 2008; 30: 223-230. [PMID: 18343261 DOI: 10.1016/j.clinthera.2008. 02.014]
9. Milkiewicz P, Wunsch E. Primary sclerosing cholangitis. Recent Results Cancer Res 2011; 185: 117-133. [PMID: 21822823]
10. Boonstra K, van Erpecum KJ, van Nieuwkerk KM, Drenth JP, Poen AC, Witteman BJ, Tuynman HA, Beuers U, Ponsioen CY. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2270-2276. [PMID: 22407885 DOI: 10.1002/ibd.22938]
11. Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9: 1092-1097; quiz e135. [PMID: 21893134 DOI: 10.1016/j.cgh.2011.08.027]
12. Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ. PSCIBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-96. [PMID: 15591511 DOI: 10.1136/gut.2004.046615]
13. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-877. [PMID: 7439807]
14. Schrumpf E, Elgjo K, Fausa O, Gjone E, Kolmannskog F, Ritland S. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15: 689-697. [PMID: 7209379]
15. Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer- Habibi A, Sadatsafavi M. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol 2005; 20: 366-370. [PMID: 15740478 DOI: 10.1111/j.1440-1746.2005.03727.x]
16. Lundqvist K, Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40: 451-456. [PMID: 9106695]
17. Marelli L, Xirouchakis E, Kalambokis G, Cholongitas E, Hamilton MI, Burroughs AK. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011; 60: 1224-1228. [PMID: 21402617 DOI: 10.1136/gut.2010.235408]
18. Ye BD, Yang SK, Boo SJ, Cho YK, Yang DH, Yoon SM, Kim KJ, Byeon JS, Myung SJ, Yu CS, Yun SC, Kim JH. Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea. Inflamm Bowel Dis 2011; 17: 1901-1906. [PMID: 21830268 DOI: 10.1002/ibd.21569]
19. Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, ten Kate F, van Deventer SJ. A doubleblind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 2008; 42: 522-526. [PMID: 18344886]
20. Regueiro M, Chopra K, Slivka A. Improvement of liver function tests in patients with primary sclerosing cholangitis and Crohn's disease treated with infliximab. Gastroenterology 2003; 124: A526
21. Bo X, Broome U, Remberger M, Sumitran-Holgersson S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 2001; 49: 131-141. [PMID: 11413121 DOI: 10.1136/gut.49.1.131]
22. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004; 49: 1-4. [PMID: 14992426]